BioSpace News Archive

AIkido Pharma Inc. announced it has extended its previously disclosed exclusive option agreement with the University of Maryland, Baltimore for the technology set forth in Patent number 10,434,116 “Methods of Treating Coronavirus Infection.” The present invention provides methods for treating a coronavirus infection.

Assessing clinical data across the lifespan identified the impact of genetic epilepsies on affected children’s lives

American Gene Technologies (AGT) announced today approval by the FDA (Food and Drug Administration) to begin Phase 1, the first human clinical trial for AGT’s lead HIV program . AGT will conduct its Phase 1 study at clinical sites in the Baltimore/D.C. area, and has named Washington Health Institute, University of Maryland, Institute of Human Virology and Georgetown University as its initial trial sites. These sites are expected to

Medtronic plc (NYSE:MDT) announced today that it will report financial results for its first quarter of fiscal year 2021 on Tuesday, August 25, 2020. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at http://newsroom.medtronic.com . The news release will include summary financial information for the company’s first quarter of fiscal year 2021, which ended on Friday, July 31, 2020. Medtroni

Confluent Medical Technologies, a global leader in contract manufacturing of specialized medical devices, announced the opening of its new Complex Catheter Design and Development Center in Austin, Texas.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced the grant of inducement awards to seven new employees.

Saillant Therapeutics, an innovative biotechnology start-up, developing promising small molecule-based therapies, today announced the swift advancement of an innovative groundbreaking generic virus-inhibiting treatment platform based on activation of a cellular master regulator

Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Seres Therapeutics, Inc., a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease, announced that it is commencing an underwritten registered public offering of 8,000,000 shares of its common stock.

Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the second quarter ended June 30, 2020. “The second quarter was an exciting time for the Company, as we continued to advance our late stage programs towards regulatory submission and commercial launch,”